4 Healthcare Stock Stories Prescribed for Investors

Teva Pharmaceutical Industries (NYSE:TEVA): Closing price $38.77

Teva, the maker of the market-leading multiple sclerosis drug Copaxone, has filed a petition with the FDA through which it hopes to delay entry into the market of a rival drug, BG-12, developed by Biogen IDEC (NASDAQ:BIIB). The petition requests that the agency not okay  any new multiple sclerosis drug until its safety has been studied by a panel of outside advisors and also revealed that it has found “troubling information” on a publicly accessible website regarding the safety of Biogen’s drug.

teva

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Premium Newsletters

Stock Investor Cheat Sheet

Stock Investor Cheat Sheet®

The ultimate Cheat Sheet for finding winning stock picks.
Learn More

Gold & Silver Newsletter

Gold & Silver

Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More

Commodities Premium Newsletter

Commodities Premium

There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more

ETF Investing

ETF Investing

At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business